Bioventix Plc

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: GB00B4QVDF07
GBP
14.50
-13.5 (-48.21%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROE of 72.09%

 
2

Company has a low Debt to Equity ratio (avg) at times

 
3

Healthy long term growth as Net Sales has grown by an annual rate of 4.94%

 
4

Flat results in Jun 25

5

With ROE of 65.66%, it has a attractive valuation with a 7.01 Price to Book Value

6

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Miscellaneous

stock-summary
Market cap

GBP 74 Million (Micro Cap)

stock-summary
P/E

11.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1,051.58%

stock-summary
Debt Equity

-0.44

stock-summary
Return on Equity

65.66%

stock-summary
Price to Book

6.45

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-48.03%
0%
-48.03%
6 Months
-60.27%
0%
-60.27%
1 Year
-63.75%
0%
-63.75%
2 Years
-60.97%
0%
-60.97%
3 Years
-61.07%
0%
-61.07%
4 Years
-65.06%
0%
-65.06%
5 Years
-65.88%
0%
-65.88%

Bioventix Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
4.94%
EBIT Growth (5y)
4.20%
EBIT to Interest (avg)
9.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
1.09
Tax Ratio
23.35%
Dividend Payout Ratio
103.26%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
176.36%
ROE (avg)
72.09%

Valuation key factors

Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
7.01
EV to EBIT
7.76
EV to EBITDA
7.69
EV to Capital Employed
11.73
EV to Sales
5.79
PEG Ratio
NA
Dividend Yield
966.78%
ROCE (Latest)
151.05%
ROE (Latest)
65.66%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Bioventix Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is -3.68% vs 6.25% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is -6.17% vs -3.57% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "13.10",
          "val2": "13.60",
          "chgp": "-3.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.90",
          "val2": "10.70",
          "chgp": "-7.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7.60",
          "val2": "8.10",
          "chgp": "-6.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "745.40%",
          "val2": "778.80%",
          "chgp": "-3.34%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Jun'25stock-summary

Jun'25
Jun'24
Change(%)
Net Sales
13.10
13.60
-3.68%
Operating Profit (PBDIT) excl Other Income
9.90
10.70
-7.48%
Interest
0.00
0.00
Exceptional Items
0.00
-0.20
100.00%
Consolidate Net Profit
7.60
8.10
-6.17%
Operating Profit Margin (Excl OI)
745.40%
778.80%
-3.34%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2025 is -3.68% vs 6.25% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2025 is -6.17% vs -3.57% in Jun 2024

stock-summaryCompany CV
About Bioventix Plc stock-summary
stock-summary
Bioventix Plc
Miscellaneous
Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors.
Company Coordinates stock-summary
Company Details
7 Romans Business Park, East Street , FARNHAM None : GU9 7SX
stock-summary
Tel: 44 1252 728001
stock-summary
Registrar Details